论文部分内容阅读
大剂量放、化疗后进行自体骨髓移植 ( ABMT)或外周血干细胞移植 ( PBSCT)治疗高危或复发非霍奇金淋巴瘤 ( NHL)已取得良好疗效 ,但复发仍是治疗失败的主要原因。越来越多的证据表明 ,体内残留或回输的肿瘤细胞可导致复发 ,缩短病人的生存期 [1～ 4 ]。因此 ,检测体内和移植物中
High dose, chemotherapy, autologous bone marrow transplantation (ABMT) or peripheral blood stem cell transplantation (PBSCT) treatment of high-risk or recurrent non-Hodgkin’s lymphoma (NHL) has achieved good results, but the recurrence is still the main reason for treatment failure. There is growing evidence that tumor cells that remain or are transfused in the body can lead to recurrence and shorten the patient’s survival [1-4]. Therefore, in vivo and in grafts are tested